BC
ODT

Broadfin Capital’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Broadfin Capital’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-93,081
Closed -$2.06M – 60
2018
Q2 		$2.06M Buy
+93,081
New +$2.17M 0.32% 44

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Broadfin Capital's ODT Position: Q3 2018 in Review

Broadfin Capital sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2018, closing a stake of 93,081 shares — an estimated $2.06M sold.

Broadfin Capital first reported a position in ODT in Q2 2018 and held it in 1 quarter. The position peaked at $2.06M in Q2 2018. 52 funds tracked by Wall St. Rank hold ODT as of Q3 2018.

  • Broadfin Capital reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Broadfin Capital sold 93,081 Odonate Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $2.06M.
  • Broadfin Capital first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Broadfin Capital's Odonate Therapeutics, Inc. Common Stock position peaked at $2.06M in Q2 2018.
  • 52 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Broadfin Capital's 13F filing for Q3 2018, filed 14 Nov 2018.